Article Text

Download PDFPDF

4CPS-207 Improving the safety of pharmacotherapy in paediatric haemato-oncology by clinical pharmacy services
  1. C Gradwohl1,
  2. H Pichler1,
  3. G Engstler1,
  4. F Nagele2,
  5. M Anditsch2,
  6. G Stemer2
  1. 1St Anna Children’s Hospital, Department of Paediatics, Medical University of Vienna, Vienna, Austria
  2. 2University Hospital AKH, Pharmacy Department, Vienna, Austria


Background and importance Prevention of drug-related problems (DRP) beneficially affects patient outcomes. Children who are treated for haemato-oncological diseases or who are receiving a haematopoietic stem cell transplantation (HSCT) are highly susceptible to DRP. Paediatric clinical pharmacy services (CPS) showed a positive impact on several outcome measures including reduction of DRP.

Aim and objectives This evaluation aimed to assess the impact of CPS in a paediatric tertiary care centre specialising in haemato-oncology by quantifying DRP and pharmaceutical interventions (PI), determining their acceptance rate, rating their clinical significance and estimating economic benefit.

Material and methods From June until December 2020, a clinical pharmacist (CP) provided CPS, which included medication reviews and subsequent ward round participations (A: haemato-oncology, 11 beds; B: HSCT unit, 10 beds). The CP and an independent expert panel consisting of two clinical pharmacists and two paediatric haemato-oncologists assessed the PI for clinical significance.1 Economic benefit was estimated retrospectively by drug therapy cost reductions and avoided follow-up costs based on prevention and management of adverse drug reactions (ADR).2

Results During 32 ward rounds, 230 DRP were addressed in 36 children (median age 7 (0.4–17) years). The acceptance rate for PI was 73.5%. The most common DRP concerned need for drug monitoring, need for information/therapy discussion and drug–drug interactions; the most common PI were drug-monitoring, drug-information and dose adjustments. The CP assessed 66% of PI as very significant or significant and correlation with the expert rating was significant (p≤0.0001). Costs of CPS were €7200. PI led to estimated drug therapy cost reductions of €5500. Prevention of 11 and identification of 24 ADR led to estimated avoided follow-up costs of €14 300–€27 500 and €31 200, respectively.

Conclusion and relevance This evaluation showed that CPS for a tertiary care centre specialising in paediatric haemato-oncology is capable of identifying and preventing DRP by clinically significant PI. The estimated economic benefit of CPS was at least six-fold higher than its costs. Based on the results, CPS were expanded in our hospital.

References and/or acknowledgements 1. Hatoum HAT, et al. Physicians’ review of significant interventions by clinical pharmacists in inpatient care. Drug Intell Clin Pharm 1988;22:980–982.

2. Zuba Martin AK. (2016) Evaluation Pilotprojekte ‘Polypharmazie’. Gesundheit Österreich, Wien.

Conflict of interest No conflict of interest

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.